Filtered By:
Condition: Atrial Fibrillation
Countries: Canada Health
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 200 results found since Jan 2013.
Variation in bleeding risk estimates among online calculators: Cross-sectional study of apps used by and for patients with atrial fibrillation
CONCLUSION: Inconsistencies and a lack of precision were observed in annual risk estimates and risk stratification produced by Web and mobile bleeding risk calculators for patients with atrial fibrillation. Clinicians should refer to annual bleeding risks observed in major randomized controlled trials to inform risk estimates communicated to patients.PMID:35418403 | PMC:PMC9007121 | DOI:10.46747/cfp.6804e127
Source: Canadian Family Physician Medecin de Famille Canadien - April 14, 2022 Category: Primary Care Authors: Ryan Pelletier Jeff Nagge John-Michael Gamble Source Type: research
Central retinal artery occlusion: a retrospective study of disease presentation, treatment, and outcomes
CONCLUSIONS: The majority of patients with CRAO presented to eye care providers, and few present within the potential window for thrombolysis of 4.5 hours, highlighting the need for public awareness strategies. Our cohort highlights the significant rate of systemic comorbidity that exists in these patients.PMID:35307340 | DOI:10.1016/j.jcjo.2022.02.015
Source: Canadian Journal of Ophthalmology - March 21, 2022 Category: Opthalmology Authors: Meghan J Smith Matthew D Benson Matthew Tennant Imran Jivraj Source Type: research
Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation
Conclusions: The results of this population-based study suggest that low-dose dabigatran has a better effective composite than warfarin. Compared with apixaban, low-dose dabigatran had a better effectiveness composite but a worse safety profile. Low-dose apixaban had a better safety composite than warfarin and other low-dose DOACs. Given that the comparative effectiveness and safety seem to vary from one DOAC to another, pharmacokinetic data for specific populations are now warranted.
Source: Frontiers in Pharmacology - January 14, 2022 Category: Drugs & Pharmacology Source Type: research
Cardiovascular disease and the risk of dementia: a survival analysis using administrative data from Manitoba
CONCLUSION: A diagnosis of CVD is associated with an increased risk of a future diagnosis of dementia. Promoting good cardiovascular health may serve as an effective measure for preventing dementia.PMID:35025100 | DOI:10.17269/s41997-021-00589-2
Source: Canadian Journal of Public Health - January 13, 2022 Category: International Medicine & Public Health Authors: Luc Clair Hope Anderson Christopher Anderson Okechukwu Ekuma Heather J Prior Source Type: research
Long-Term Outcomes for Patients With Acute Coronary Syndrome and Nonvalvular Atrial Fibrillation
Short-term outcomes are worse for patients with acute coronary syndrome (ACS) with a history of nonvalvular atrial fibrillation (NVAF). However, long-term prognosis remains unclear. We linked administrative health databases to identify patients hospitalized with ACS (ST-elevation myocardial infarction [STEMI], non –STEMI [NSTEMI], and unstable angina) between 2008 and 2019 in Alberta, Canada. Patients were stratified according to history of NVAF before hospitalization. The primary outcome was a composite of all-cause mortality, hospitalization for myocardial infarction, or stroke at 3 years.
Source: The American Journal of Cardiology - January 7, 2022 Category: Cardiology Authors: Pishoy Gouda, Douglas C. Dover, Anamaria Savu, Kevin Bainey, Shaun G. Goodman, Robert Welsh, Padma Kaul, Roopinder Kaur Sandhu Source Type: research
Warfarin adherence and anticoagulation control in atrial fibrillation patients: a systematic review
CONCLUSIONS: While the available evidence is limited, this systematic review demonstrated a positive finding of the association between warfarin adherence and anticoagulation control in patients with AF.PMID:34982455 | DOI:10.26355/eurrev_202112_27642
Source: European Review for Medical and Pharmacological Sciences - January 4, 2022 Category: Drugs & Pharmacology Authors: M Ababneh S A Nasser A Rababa'h F Ababneh Source Type: research
